Introduction: We sought to determine if proteomic profiles could predict risk for incident mild cognitive impairment (MCI) and Alzheimer's disease (AD) among adults with Down syndrome (DS). Methods: In a cohort of 398 adults with DS, a total of n = 186 participants were determined to be non-demented and without MCI or AD at baseline and throughout follow-up; n = 103 had incident MCI and n = 81 had incident AD. Proteomics were conducted on banked plasma samples from a previously generated algorithm. Results: The proteomic profile was highly accurate in predicting incident MCI (area under the curve [AUC] = 0.92) and incident AD (AUC = 0.88). For MCI risk, the support vector machine (SVM)-based high/low cut-point yielded an adjusted hazard ratio (HR) = 6.46 (P <.001). For AD risk, the SVM-based high/low cut-point score yielded an adjusted HR = 8.4 (P <.001). Discussion: The current results provide support for our blood-based proteomic profile for predicting risk for MCI and AD among adults with DS.
|Journal||Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring|
|State||Published - 2020|
- Down syndrome
- mild cognitive impairment